Published in Cancer on August 25, 2011
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM) | NCT03992170
Therapeutic advancements in multiple myeloma. Front Oncol (2014) 0.96
A case of multiple myeloma presenting as scalp swelling with intracranial extension. J Neurosci Rural Pract (2013) 0.84
Astrocytoma development following complete multiple myeloma remission in a 49-year-old patient: A case report. Exp Ther Med (2013) 0.75
Oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature. Case Rep Hematol (2014) 0.75
An Unusual Cause of Altered Mental Status in Multiple Myeloma: An Extraosseous Manifestation. Hawaii J Med Public Health (2016) 0.75
Commentary. J Neurosci Rural Pract (2013) 0.75
Multiple myeloma with intracranial extension and bilateral renal infiltration: A case report and review of the literature. Oncol Lett (2015) 0.75
Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head. J Int Med Res (2016) 0.75
Extradural plasmacytoma with central nervous system involvement in newly diagnosed multiple myeloma. Int J Hematol (2017) 0.75
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med (2005) 4.96
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol (2005) 3.81
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Lung ultrasound characteristics of community-acquired pneumonia in hospitalized children. Pediatr Pulmonol (2012) 3.63
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol (2013) 3.58
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica (2006) 3.41
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med (2015) 3.05
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood (2011) 2.74
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma (2014) 2.66
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol (2013) 2.63
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53
Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma (2007) 2.41
Mucormycosis in hematologic patients. Haematologica (2004) 2.40
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med (2016) 2.36
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol (2004) 2.36
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica (2002) 2.34
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol (2010) 2.24
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol (2009) 2.19
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol (2007) 2.14